
USPH Stock Forecast & Price Target
USPH Analyst Ratings
Bulls say
US Physical Therapy is expected to experience strong revenue growth in the coming months due to the implementation of two announced hospital partnerships and the potential for additional health system partnerships. Furthermore, with operating expenses expected to improve by 180-bps and other expenses anticipated to be 20.8% of revenue, the company's profitability and financial performance are expected to improve significantly. Additionally, the impact of Medicaid rate pressure is relatively minimal, further supporting a positive outlook on the company's stock.
Bears say
US Physical Therapy is currently trading at 10.7x its 2026 EBITDA estimate, lower than its average of 15x since mid-2023. However, the analyst remains constructive on the company due to potential growth from improved Medicare rates, accretive M&A, and the company's new hospital channel strategy. With a trough valuation and a double-digit profit growth profile, the risk-reward profile is seen as asymmetric, leading the analyst to remain positive on USPH despite recent sector multiple compression.
This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.
USPH Analyst Forecast & Price Prediction
Start investing in USPH
Order type
Buy in
Order amount
Est. shares
0 shares